Comparison of the Efficacy and Safety of PARP Inhibitors as a Monotherapy for Platinum-Sensitive Recurrent Ovarian Cancer: A Network Meta-Analysis

BackgroundThe present COVID-19 pandemic has tended toward normality. To provide convenient, safe, and effective home treatment programs for patients with recurrent ovarian cancer (ROC), the clinical efficacy and safety of poly (ADP-ribose) polymerase inhibitor (PARPi) (including olaparib, niraparib,...

Descripción completa

Guardado en:
Detalles Bibliográficos
Autores principales: Hongmei Wang, Meng Wu, Haonan Liu, Hang Zhou, Yang Zhao, Yifan Geng, Bo Jiang, Kai Zhang, Bo Zhang, Zhengxiang Han, Xiuping Du
Formato: article
Lenguaje:EN
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://doaj.org/article/e00c21c0a78545cf8388c7f9481eb334
Etiquetas: Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!

Ejemplares similares